Investment Analysts’ Weekly Ratings Updates for Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE: JNJ) recently received a number of ratings updates from brokerages and research firms:

• 10/31/2025 – Johnson & Johnson had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 10/22/2025 – Johnson & Johnson was given a new $190.00 price target on by analysts at Johnson Rice. They now have a “hold” rating on the stock.
• 10/22/2025 – Johnson & Johnson was given a new $190.00 price target on by analysts at Loop Capital.
• 10/20/2025 – Johnson & Johnson was upgraded by analysts at Daiwa America from a “hold” rating to a “strong-buy” rating.
• 10/20/2025 – Johnson & Johnson was upgraded by analysts at Daiwa Capital Markets from a “neutral” rating to an “outperform” rating. They now have a $203.00 price target on the stock.
• 10/16/2025 – Johnson & Johnson had its price target raised by analysts at HSBC Holdings plc from $210.00 to $215.00. They now have a “buy” rating on the stock.
• 10/15/2025 – Johnson & Johnson was given a new $210.00 price target on by analysts at Argus.
• 10/15/2025 – Johnson & Johnson had its price target raised by analysts at Raymond James Financial, Inc. from $174.00 to $209.00. They now have an “outperform” rating on the stock.
• 10/15/2025 – Johnson & Johnson was given a new $190.00 price target on by analysts at Morgan Stanley.
• 10/15/2025 – Johnson & Johnson had its price target raised by analysts at Stifel Nicolaus from $165.00 to $190.00. They now have a “hold” rating on the stock.
• 10/15/2025 – Johnson & Johnson had its price target raised by analysts at Citigroup Inc. from $213.00 to $215.00. They now have a “buy” rating on the stock.
• 10/15/2025 – Johnson & Johnson had its price target raised by analysts at Bank of America Corporation from $198.00 to $204.00. They now have a “neutral” rating on the stock.
• 10/14/2025 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 10/14/2025 – Johnson & Johnson had its price target raised by analysts at UBS Group AG from $190.00 to $214.00. They now have a “buy” rating on the stock.
• 10/10/2025 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $209.00 price target on the stock.
• 10/10/2025 – Johnson & Johnson had its price target raised by analysts at Morgan Stanley from $176.00 to $178.00. They now have an “equal weight” rating on the stock.
• 10/9/2025 – Johnson & Johnson had its price target raised by analysts at The Goldman Sachs Group, Inc. from $186.00 to $212.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Johnson & Johnson was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 10/7/2025 – Johnson & Johnson had its price target raised by analysts at Citigroup Inc. from $200.00 to $213.00. They now have a “buy” rating on the stock.
• 10/6/2025 – Johnson & Johnson had its price target raised by analysts at Sanford C. Bernstein from $172.00 to $193.00. They now have a “market perform” rating on the stock.
• 10/3/2025 – Johnson & Johnson was given a new $198.00 price target on by analysts at UBS Group AG.
• 10/3/2025 – Johnson & Johnson was given a new $212.00 price target on by analysts at Wells Fargo & Company. They now have an “overweight” rating on the stock.
• 10/3/2025 – Johnson & Johnson was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $212.00 price target on the stock, up previously from $170.00.
• 10/3/2025 – Johnson & Johnson had its price target raised by analysts at Bank of America Corporation from $175.00 to $198.00. They now have a “neutral” rating on the stock.
• 9/30/2025 – Johnson & Johnson had its price target raised by analysts at HSBC Holdings plc from $188.00 to $210.00.
• 9/27/2025 – Johnson & Johnson had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/23/2025 – Johnson & Johnson was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $206.00 price target on the stock, up previously from $167.00.
• 9/19/2025 – Johnson & Johnson had its price target raised by analysts at The Goldman Sachs Group, Inc. from $185.00 to $186.00. They now have a “buy” rating on the stock.
• 9/16/2025 – Johnson & Johnson had its price target raised by analysts at JPMorgan Chase & Co. from $185.00 to $200.00. They now have a “neutral” rating on the stock.
• 9/13/2025 – Johnson & Johnson was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is currently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.